Health Care·Pharmaceuticals·$3.0B
Nektar Therapeutics (NKTR) is a biotechnology company focused on developing innovative therapies for patients with serious diseases. Operating in the healthcare sector, it plays a crucial role in advancing pharmaceutical treatments, particularly in areas like cancer and autoimmune diseases.
EPS
Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
2Q
EPS Beat Rate
63%
Avg EPS Surprise
-161.09%
Avg Stock Reaction
-0.58%
In the last quarter, Nektar reported an EPS of $-1.78, which was better than analysts expected, resulting in a positive surprise. However, the stock fell by 4.05% the following day, indicating mixed market reactions.
Management Promises & Guidance
Analysts are expecting Nektar to report a loss of $-1.60 per share on revenues of $11 million for Q1-2026. The outlook is cautious, given the company's recent history of mixed earnings results.
Bull Case
If Nektar can exceed revenue expectations and show signs of improving its product pipeline, it could lead to a significant positive reaction in the stock price.
Bear Case
Conversely, if the company fails to meet earnings expectations or provides disappointing guidance, it could lead to a sharp decline in the stock.
EPS
$-1.60Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$11MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will Nektar's revenue reach or exceed the $11 million consensus estimate?
Meeting or exceeding this revenue target could indicate stronger demand for its products and improve investor confidence.
Q2
What updates will management provide on the development pipeline?
Insights into ongoing projects could significantly influence market perceptions of the company's future growth potential.
Why consensus could be wrong
The Street may underestimate the potential for revenue growth driven by recent advancements in Nektar's product pipeline, which could lead to better-than-expected results.
Supporting Evidence
Nektar has a history of surprising on earnings, with a 63% beat rate over the last eight quarters.
Options pricing suggests a significant move, indicating that investors are bracing for volatility, which could be due to positive developments not yet reflected in consensus estimates.
Key Risk
If revenue comes in below $6 million, it could undermine the growth narrative and lead to a swift market reaction.
Pre-commit to what would confirm each case.
This quarter's results will be closely scrutinized as they could either validate or challenge the company's growth narrative.
Bull Confirmed If
Revenue exceeding $11 million and positive commentary on product development would confirm the bull case.
Bear Confirmed If
Revenue falling below $6 million would support the bear case.
Implied Move
±16.1%
Historical Avg
±2.2%
The options market is pricing in a significant potential move in either direction, indicating uncertainty about the upcoming earnings report.
Options are pricing ±16.1% while NKTR has averaged ±2.2% over the last 8 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Nektar beats expectations, history suggests a potential average one-day move of +1.25%, confirming a bullish outlook.
In-Line / Cautious
An in-line report could lead to muted reactions, with the stock possibly moving within the historical average range.
Miss
If the company misses expectations, history suggests a potential average one-day move of +0.54%, which could indicate further investor caution.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026